Symptomatic Severe Bradycardia during Pazopanib Treatment Pazopanib Tedavisi Sırasında Semptomatik Şiddetli Bradikardi

ZORKUN C. S., Eren Ö. A.

Turk Kardiyoloji Dernegi Arsivi, cilt.53, sa.2, ss.140-142, 2025 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 53 Sayı: 2
  • Basım Tarihi: 2025
  • Doi Numarası: 10.5543/tkda.2024.03788
  • Dergi Adı: Turk Kardiyoloji Dernegi Arsivi
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.140-142
  • Anahtar Kelimeler: Angiosarcoma, cardiotoxicity, pazopanib, permissive cardiotoxicity
  • İstanbul Üniversitesi Adresli: Evet

Özet

Pazopanib, a tyrosine kinase inhibitor that targets growth factor receptors, is associated with various side effects, including bradycardia. We report a severe case of symptomatic bradycardia, with a heart rate dropping to 28 beats per minute, in a patient with cardiac angiosarcoma treated with 800 mg/day of pazopanib. Reducing the dosage to 600 mg/day improved the heart rate to 53 beats per minute. This case highlights the risk of severe bradycardia associated with pazopanib, emphasizing the need for vigilant heart rate monitoring.